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EBV Genome Mutations and 
Malignant Proliferations
Sylvie Ranger-Rogez
Abstract
The Epstein-Barr virus (EBV) is a DNA virus with a relatively stable genome. 
Indeed, genomic variability is reported to be around 0.002%. However, some 
regions are more variable such as those carrying latency genes and specially 
EBNA1, -2, -LP, and LMP1. Tegument genes, particularly BNRF1, BPLF1, and 
BKRF3, are also quite mutated. For a long time, it has been considered for this 
ubiquitous virus, which infects a very large part of the population, that particular 
strains could be the cause of certain diseases. However, the mutations found, in 
some cases, are more geographically restricted rather than associated with prolif-
eration. In other cases, they appear to be involved in oncogenesis. The objective of 
this chapter is to provide an update on changes in viral genome sequences in malig-
nancies associated with EBV. We focused on describing the structure and function 
of the proteins corresponding to the genes mentioned above in order to understand 
how certain mutations of these proteins could increase the tumorigenic character 
of this virus. Mutations described in the literature for these proteins were identified 
by reporting viral and/or cellular functional changes as they were described.
Keywords: Epstein-Barr virus, lymphoma, carcinoma, mutation, sequence, next 
generation sequencing
1. Introduction
Epstein-Barr virus (EBV), a ubiquitous gamma-herpesvirus, infects the vast 
majority of the worldwide human population. This virus was initially discovered in 
cultured lymphoma cells from patients with Burkitt’s lymphoma (BL) in 1964 [1]. 
During the primary infection, EBV infects epithelial cells of the oropharynx where it 
actively replicates and also infects B cells where it establishes a life-long latency in the 
form of an episome located in the host cell nucleus. During latency, EBV may produce 
nine viral latency proteins, including six so-called “Epstein-Barr Nuclear Antigens” 
(EBNA1, -2, -3A, -3B, -3C, and -LP), involved in transcriptional regulation, and three 
“Latent Membrane Proteins” (LMP1, -2A, and -2B), mimicking signals needed for 
B cell maturation, as well as two small noncoding RNAs (EBER-1 and EBER-2), 
BamHI-A rightward transcripts (BARTs), and miRNAs. Four different latency 
programs can be identified, based on the proteins that are expressed (Table 1). EBV 
primary infection, which occurs more often in childhood, is usually asymptomatic 
in children, whereas it may be responsible for infectious mononucleosis (IM) in 
teenagers or young adults in western countries. In addition to this nonmalignant 
disease, EBV can also be associated with diverse malignant pathologies. In par-
ticular, EBV is involved in the development of several malignancies of lymphoid 
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origin including endemic Burkitt’s lymphoma [2], nasal NK/T lymphoma [3], 
some Hodgkin’s lymphoma [4], and B- or T-cell lymphoproliferations in immuno-
compromised patients [5]. It is also implicated in epithelial malignancies such as 
undifferentiated nasopharyngeal carcinoma (NPC) [6] and 10% of cases of gastric 
carcinoma [7]. Although populations from all geographic areas are infected by 
the virus, the incidence of the pathologies in which it occurs varies significantly 
depending on the region [8]. For example, BL occurs mainly in children living in 
sub-Saharan Africa [9], and the prevalence of NPC is particularly high in adults 
living in Southern China, Southeast Asia, and Northern Africa [10]. The differences 
observed in the geographic distribution of these pathologies suggest that there 
could be various genetic variants of EBV, of different global distributions, and with 
different levels of transforming capacity. This question of a specific disease variant 
is raised by many authors and is still being debated. In this chapter, we wish to take 
inventory of the state of knowledge concerning the variability observed on the 
most mutated genes among all EBV genes and the possible implications in human 
pathology.
2. Evolving knowledge of the EBV genome
The fact that the viral genome is relatively large (175 kb), that it is made up of 
DNA, therefore less variable than if it was an RNA genome, and that it carries repet-
itive regions, limited its sequencing for a long time. The first published sequences 
were small fragments of the B95-8 genome; then, the entire B95-8 genome was 
sequenced in 1984 [11]. The B95-8 strain was the first cultured EBV cell line able to 
secrete large amounts of viral particles into the culture medium. It was originally 
obtained from a spontaneous human lymphoblastoid cell line (LCL) established 
from a North American case of infectious mononucleosis, the 883L cell line, whose 
virus was used to transform lymphocytes from a cotton top marmoset. Since it was 
the first strain with a fully published genome, B95-8 has been extensively studied 
and mapped for transcripts, promoters, and open reading frames.
This first EBV whole genome sequencing was followed by others, and complete 
viral genome sequences of the cell lines AG876, originating from a Ghanaian case 
of African BL [12] and GD1, obtained from cord B cells infected with EBV from 
saliva of an NPC patient in Guangzhou, China [13] were published. Sequences of 
some genes, mainly latency genes, were also studied, especially in lines established 
from patients [14, 15]. B95-8, GD1, and AG876 were sequenced by conventional 
Program EBV expressed proteins Active promoters B cell type
Latency III Growth EBNA-1, -2, -3A, -3B, -3C, -LP Initially Wp Naive B cells
LMP-1, -2A-, -2B Then Cp
LMP promoters
EBER-1 and -2p
Latency II Default EBNA-1 Qp, EBER-1 and -2p
LMP-1, -2A, -2B LMP promoters
Latency I Latency EBNA-1 Qp, EBER-1 and -2p Resting B cells
Latency 0 No protein or LMP-2A LMP-2Ap Memory B 
cells
Table 1. 
Proteins expressed during the different latency programs.
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shotgun sequencing (Sanger’s method). The comparison of sequences obtained for 
various cell lines revealed the existence of two types of EBV: type 1 or A, of which 
B95-8 can be considered as the prototype, and type 2 or B, exemplified by AG876. 
The main difference between the two types concerns the EBNA2 gene, with only 
70% identity at the nucleotide level and 54% identity in the protein sequence [16]. 
Additional variations have also been observed in the EBNA3 genes, but to a lesser 
extent: 10, 12, and 19% of base pair differences for EBNA3A, 3B, and 3C, respec-
tively [17]. The comparison of viral sequences also highlighted that the B95-8 cell 
line has a significant 11.8 kb deletion (positions 139,724–151,554) corresponding to 
some of the BART miRNA genes, one of the origins of lytic replication [11], the LF2 
and LF3 genes, and a part of the LF1 gene. More complete sequence comprising the 
B95-8 sequence supplemented with a Raji fragment at the level of deletion has been 
constructed. It was annotated in 2010 as RefSeq HHV4 (EBV) sequence NC_007605 
and is now used as a wild-type strain reference [18].
As adaptation of the virus to in vitro culture is possible, thus generating a bias 
in the results, some authors have preferred to sequence the viral genome directly 
in samples from patients. Therefore, the sequences GD2, from a Guangzhou NPC 
biopsy, and HKNPC1, from a Hong Kong NPC biopsy, were published [19, 20], both 
using a more recent sequencing technique, “next generation sequencing” (NGS). 
This technology can be used directly on samples or after enrichment, which avoids 
artifacts due to cellular DNA. Enrichment can be achieved by PCR or cloning into 
F-factor plasmids, but most frequently, it is carried out using target DNA capture 
by hybridization. NGS delivers a wealth of information and requires extensive 
bioinformatic analysis. This technology has made it possible to rapidly increase 
the number of fully sequenced viral genomes originating from healthy subjects or 
patients and thus obtain more information.
3. The most variable regions of the genome
Authors who sequenced the entire viral genome and analyzed the genomic 
variations came to the conclusion that the latent genes harbored the highest 
numbers of nonsynonymous mutations [20–24]. For example, Liu et al. [25] 
compared the sequences of nine strains of EBV to GD1, of which they were most 
closely related, and showed that latency genes were the most mutated. In this study, 
latent and tegument genes were found to harbor 58.4 to 84.3% of all nonsynony-
mous mutations detected for each genome. Santpere et al. [26] found that latent 
genes were twice as mutated as lytic genes. The observation that the latent genes 
harbor more nucleotide diversity than lytic genes was made regardless of the type 
of pathology: nasopharyngeal carcinoma [20, 21], NK/T lymphoma [27], endemic 
Burkitt’s lymphoma [22], Hodgkin’s lymphoma [22], posttransplant lymphoprolif-
erative disease [22], gastric carcinoma [25], lung carcinoma [23], and also strains 
originating from infectious mononucleosis [22] or healthy subjects [26]. Why latent 
genes are the most variable is not clear today. By analyzing their data according to 
the Yang model [28], Santpere et al. [26] showed that the lytic genes had an evolu-
tionary constraint close to that of the host: a strong purifying selection was objecti-
fied for 11 lytic genes. However, signatures of accelerated protein evolution rates 
were found in coding regions related to virus attachment and entry into host cells. 
The latency genes, on the other hand, show a positive selection, perhaps in relation 
to the MHC, which can be the cause of their large diversity. Changes in amino acids 
(aa) often occur in immune epitopes. Amino acid changes in CD8+ epitopes were 
described in all latent proteins, while changes in CD4+ epitopes were shown only 
for EBNA1 and -2 and LMP1 and -2 [20]. However, most codons of the EBNA3 gene 
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under positive selection are not cytotoxic T-lymphocyte epitopes: either there are 
epitopes not described to date or the selection relates to other functionalities. The 
selection of mutants may depend on a difference in immunity in relation to the 
geography and/or capacity of a strain to infect and persist.
4. Variability of main latency proteins
After the virus enters a host cell, the genome circularizes through recombination 
of the terminal repeats (TRs) located at each end of the genome to form an episome 
that will be chromatinized and methylated in the same way as the human genome. 
Latent transcription programs in B cells are due to the differential activity of epige-
netically regulated promoters and take place in three successive waves. The EBNA2 
and EBNA-LP, as well as BHRF1, a bcl2 homolog, are the first viral proteins to be 
expressed, under the dependence of Wp promoter. The two expressed EBNAs and 
the cellular factor recombination signal-binding protein for immunoglobulin Kappa 
J region (RBP-Jk) activate then the Cp promoter, which drives the expression of all of 
the EBNA proteins, while Wp becomes progressively hypermethylated; the transcrip-
tion will gradually be under Cp control. Subsequently, LMP1, LMP2A, and LMP2B 
proteins are expressed due to activation of their respective promoters. During latency 
I or II, Qp promoter controls EBNA1 expression, and Cp methylation is responsible 
for the five other EBNA silencing. Methylation does not control the Qp promoter, 
which is switched off by binding to a repressor protein.
As previously developed, latency proteins show the most sequence variations, 
and among them, EBNA1, EBNA2, EBNA-LP, and LMP1 are the most mutated. The 
main properties of these proteins are reported in Table 2.
4.1 EBNA1
EBNA1, expressed in both latent and lytic EBV infections, was the first EBV pro-
tein detected. EBNA1, whose structure (Figure 1) and functions have largely been 
studied [29, 30], is a 641 aa protein. However, EBNA1 proteins frequently exhibit 
size variations due to differing numbers of gly-ala repeats (aa 89–325). During 
latency, EBNA1 is the only protein expressed in all forms of latency in proliferating 
cells and also in all EBV associated malignancies. EBNA1, which acts as a homodi-
mer, is essential for initiating EBV episome replication before mitosis, once per cell 
cycle, and mitotic segregation of EBV episomes, thus for the maintenance of EBV 
episome in latently infected cells [31]. The EBNA1 DNA-binding domain is essential 
but not sufficient for the replication function, and the N-terminal half of EBNA1 
is also required. Two EBNA1 regions (aa 8–67 and aa 325–376) are particularly 
important for this activity, and the point mutations G81 or G425 enhance EBNA1-
dependent DNA replication. Inversely, the EBNA1 aa 395–450 region mediates an 
interaction with the human ubiquitin-specific protease, USP7, which may negatively 
regulate replication. The partitioning of EBV episomes in two dividing cells requires 
two viral components: the ori P FR element and EBNA1, mainly the central Gly-Arg 
region aa 325–376 and secondarily the aa 8–67 sequence. EBNA1 also activates the 
expression of other latency genes participating in immortalization: the regions 
involved are the central Gly-Arg sequence and the 61–89 region. Interaction with 
the recognition sites located on FR, DS of ori P, and Bam-HI-Q takes place through 
binding sites located in the C-terminal of EBNA1 (aa 459-607), sequence which also 
mediates the dimerization of EBNA1 (aa 504–604). Through its interaction with 
both human casein kinase CK2 (aa 383–395) and cellular ubiquitin-specific protease 
USP7 (aa 442–448), EBNA1 is also able to disrupt promyelocytic leukemia protein 
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(PML) bodies and degrade PML. In addition to its role in latent infection, EBNA1 
can therefore participate in lytic infection by overcoming suppression by PML 
proteins [32]. Indeed, PML proteins and nuclear bodies were found to suppress lytic 
infection by EBV. Recently [33], organization in an oligomeric hexameric ring form 
was described for the EBNA1 DNA-binding domain, the oligomeric interface pivot-
ing around residue T585. Mutations occurring on this residue had both positive and 
negative effects on EBNA1-dependent DNA replication and episome maintenance.
Based on polymorphisms observed at 15 codons, Bhatia et al. [14] reported two 
strains named P (prototype) and V (variant), each having two subtypes defined 
by the aa at position 487 (P-ala, P-thr, V-pro, and V-leu). They detected mostly the 
P-thr and the V-leu variants, respectively, in African and American BL tumors, 
Protein Role/
localization
Main properties
EBNA1 Latency Initiation of viral episome replication before mitosis
Mitotic segregation of EBV episomes
Transcription of other latency genes (Cp and LMPp enhancer)
Degradation of promyelocytic leukemia protein (PML) bodies
Cellular transcription regulation
EBNA2 Latency Viral and cellular transcription factor
Initiation and maintenance of B cell immortalization
Blocking of methylation sites for BZLF-1 binding
EBNA-LP Latency Coactivator of the transcriptional activator EBNA2
LMP1 Latency Similarity to constitutively activated CD40
Constitutive activation of cell pathways
Maintenance of EBV latency and control of cell migration
BNRF1 Tegument Establishment of latency and cell immortalization
Increase in the number of cellular centrioles
BPLF1 Tegument Downregulation of viral ribonucleotide reductase (RR)
Disruption of damaged DNA repair
Decreasing of innate immunity
BKRF3 Tegument DNA replication and repair—viral DNA mutagenesis prevention
Table 2. 
Main properties of proteins developed in this chapter.
Figure 1. 
Schematic representation of basic structure of EBNA1 protein with the different motifs and their position. 
Gly-Arg: region rich in Gly-Arg; Gly-Ala: Gly-Ala repeats; CK2: interaction with human casein kinase, CK2; 
USP7: interaction with the human ubiquitin specific protease, USP7; DNA binding: DNA-binding domain; 
Dimerization: region that mediates the dimerization of EBNA1. The different mutations discussed are noted.
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but these findings were not confirmed by another group who reported different 
spectra of EBNA1 subtypes according to different geographical areas in both 
healthy patients and BL tumors [34]. A fifth subtype, V-val, was later recognized 
in South-East Asia and was found to be prevalent in NPC samples by numerous 
authors [20, 35–37]. These findings suggest that the V-val variant might adapt 
particularly well to the nasopharyngeal epithelium or that this strain possesses 
an increased oncogenic potential. Indeed, most of the variant codons, localized 
in the DNA-binding domain, may have an impact on the EBV phenotype result-
ing in impaired ability to transform B-lymphocytes [30]. However, other reports 
observed that this subtype had no tumor-specific expression [38], and it is likely 
that it probably represents a dominant EBNA1 subtype in Asian regions, not found 
in other areas of the world [8, 23, 25]. The P-thr subtype is the most commonly 
observed in peripheral blood of American and African subjects as well as in 
African tumors. In our experience, P-thr is also the most prevalent in France and 
particularly in the course of lymphoproliferative diseases.
Apart from these mutations, others have been reported. For example, Borozan 
et al. [39] looked at gastric carcinomas and mainly found two mutations already 
described in NPC, H418L and A439T, located outside the DNA-binding domain and 
common in both NPC and GC but uncommon in other EBV isolates, from lympho-
mas or healthy subjects. They also described a new mutation, T85A, positioned in 
the region required for transcriptional activation of other latency genes and thus 
able to modify this function. Wang et al. [23] described the substitution T585I. 
T585 is subject to substitutions, and T585 polymorphism is found frequently in 
NPC tumors and Burkitt’s lymphoma. T585I was previously found, and this strain 
was defective in replication and maintenance of the viral episome [40], as well as 
deficient in suppressing lytic cycle gene transcription and lytic DNA replication.
In summary, EBNA1 V-val variant seems to be a geographic variant almost exclu-
sively present in South-East Asia. Conversely, mutations T85 and T585, which occur 
in functional regions of the protein, could have biological consequences and espe-
cially the substitution T585I, which promotes lytic replication and is found in NPC.
4.2 EBNA2
EBNA2, a 487 aa protein, is expressed in vivo during latency III shortly after 
infection of B cells or in lymphomas occurring in immunocompromised patients and 
in LCL. As mentioned above, the variations in EBNA2 make it possible to classify 
EBV as types 1 and 2 (or A and B) since only 70% identity at the nucleotide level and 
54% homology in the protein sequence were observed. The overall structure of the 
EBNA2 protein (Figure 2) is characterized by poly-P and poly-RG areas, this last 
one being a protein-protein and protein-nucleic acid interaction domain important 
for efficient cell growth transformation, and nine regions conserved throughout 
the gene [41]. EBNA2 acts principally as a transcription factor and contains three 
categories of domains critical for its transcription regulation function: transactiva-
tion domains (TAD), self-association domains (SAD), and nuclear localization 
signals (NLS). EBNA2 does not bind directly to DNA. It uses cell proteins as adapt-
ers to access viral or cellular enhancer and promoter sites. The C-terminal TAD 
(aa 448–471) is able to recruit components of basic transcriptional machinery as 
well as chromatin modifiers and can bind to the viral coactivator EBNA-LP, while 
the N-terminal TAD (aa 1–58) cannot bind EBNA-LP, although its activity can be 
enhanced by this protein. Two SADs (aa 1–58 and 97–121), separated by the poly-
proline stretch, were identified in the N-terminal region [42]. An additional third one 
has been reported, localized in a nonconserved region, and flanked by the second 
SAD and the adapter region [43]. EBNA2 contributes to B-cell immortalization, and 
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it has been demonstrated that type 1 EBV, which is predominantly found in EBV-
associated diseases, immortalizes B cells in vitro much more efficiently than type 2 
[44], which is predominantly determined by sequence variation in the C-terminus 
of EBNA2 [45]. During the early events of EBV infection in resting B cells, EBNA2 
initiates the transcription of a cascade of primary and secondary viral and cellular 
target genes and therefore is responsible for the initiation of immortalization by 
reprogramming the resting state into a proliferative state. For this, EBNA2 interacts 
with chromatin remodelers and as a transcription factor cofactor [46]. Mühe et al. 
[47] demonstrated that the first 150 N-terminal aa of EBNA2 are important for the 
initiation of immortalization. EBNA2 is also involved in immortalization mainte-
nance; the region implicated here (aa 295–378) includes the conserved regions CR5 
(aa 295–307) and CR6 (aa 320–326), particularly important for this function. CR5 
mediates the contact between EBNA2 and SKIP (Ski-interacting protein), and CR6 is 
the CBF1 (C promoter-binding factor 1) or RBP-Jk targeting domain. Mechanisms to 
initiate and maintain B cell immortalization are not completely understood today.
Wang et al. [41], working on 25 EBV-associated GCs, 56 NPCs, and 32 throat 
washings from healthy donors in Northern China, described 4 EBNA2 subtypes 
according to the presence of a deletion, namely subtypes E2-A (no aa deletion), E2-B 
(aa 294Q deletion), E2-C (aa 357K and 358G deletion), and E2-D (aa 357K, 358G, and 
294Q deletion). The E2-A subtype exhibited six nonsilent mutations, P291T, R413G, 
I438L, E476G, P484H, and I486T; the substitution P291T was present in six NPC 
E2-D and six NPC E2-C. The substitution R413G was detected in E2-C for one patient. 
They found that E2-A and E2-C were dominant in the samples they analyzed and that 
the E2-D pattern was detected only in the NPC specimens. The mutation R163M was 
detected in all samples. This mutation has previously been described worldwide and 
in different diseases.
Mutations 357 and 358 occurred in the RG domain (aa 335–362), a downregu-
lator of EBNA2 activation of the LMP1 promoter [48]. Moreover, aa 357–363 
(KGKSRDK) constitutes the PKC phosphorylation site, which can reduce the 
amounts of EBNA2/CBF1 complex formed. EBNA2 is suspected to be involved in 
the development of malignancies as a result of sequence variations most frequently 
affecting its regulation function.
Interestingly, EBNA2 entire-gene deletion has been shown in some endemic BL 
cell lines such as P3HR1, Daudi, Sav, Oku, and Ava [49]; it remains to determine if 
this deletion occurs classically in vivo in African BL.
In short, geographic variants were not formally demonstrated for EBNA2. 
Among the described mutations, the most interesting are those occurring in the 
PKC phosphorylation site because they can activate the Cp and/or LMP1p and thus 
increase the production of latency proteins.
Figure 2. 
Schematic representation of basic structure of EBNA2 protein with the different motifs and their position. 
The two transactivation domains (TADs), the three self-association domains (SADs), and the two nuclear 
localization signals (NLSs) are mentioned. Poly P: area rich in P; PolyRG: area rich in RG; CR5: conserved 
region 5, which interacts with SKIP (Ski-interacting protein); CR6: conserved region 6, which interacts with 
CBF1 (C promoter-binding factor 1). The different mutations discussed are mentioned.
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4.3 EBNA-LP (EBNA-leader protein)
EBNA-LP, like EBNA2 and concomitantly with EBNA2, is expressed shortly after 
the infection of B cells in healthy individuals as well as in EBV-related malignant 
diseases in immunodeficient patients and LCLs. EBNA-LP acts mostly as a coactivator 
of the transcriptional activator EBNA2, thus inducing the expression of some cellular 
genes, including cyclin D2 [50], or viral genes, that is, LMP1 [51], LMP2b, and Cp 
and therefore having an important role in B cell immortalization. EBNA-LP also 
can directly interact with several cell proteins such as tumor suppressors or proteins 
involved in apoptosis or cell cycle regulation.
EBNA-LP is comprised of a variable number of 66 aa repetitive units, corre-
sponding to the variable number of W1 and W2 exons located in the EBV internal 
repeat IR1, followed by a unique 45 aa domain, encoded by two unique 3′ exons Y1 
and Y2 (Figure 3). Therefore, EBNA-LP protein may vary in size according to the 
number of W1–W2 repeats contained in each EBV isolate. By convention, the pro-
tein annotation is based on a single W repeat isoform (Figure 4). In this configura-
tion, the protein has 110 aa. Conserved regions were identified in the N extremity 
of the protein (CR1 to CR3, respectively, aa 11–33, 45–52, and 55–62, implicated 
in EBNA2 binding), and in the C-terminal region (CR4 and CR5, respectively, aa 
76–82 and 101–110). CR3 and a serine within W2 (S35) were demonstrated to be 
important for EBNA2 coactivation. EBV-mediated B cell immortalization maps to 
the W1W2 repeated domains and requires at least two IR1 repetitions to be effec-
tive, but a number greater than or equal to 5 is optimal [52]. Some interactions 
with cell proteins are mediated by the repeated W1W2 N-terminus [53]. EBNA-LP 
gene transcription initiates from the W promoter (Wp) residing in each IR1 repeat 
during the early stages of infection, and multiple EBNA-LP protein isoforms are 
produced. During the later stages of infection and in LCLs, transcription initiates 
from the C promotor (Cp) [54]. The level of transcription initiated by Cp compared 
to Wp varies according to different circumstances [55].
About 15% of BL tumors host a virus, which uses exclusively the W promoter, 
expressing an EBV atypical latency program [49], harboring EBNA1, EBNA3A, 3B, 
3C, and a truncated form of EBNA-LP. In these cases, EBV genome lacks the EBNA2 
Figure 3. 
Schematic representation of the IR1 region of EBV genome (according to Ref. [113]). The promoters Wp, Cp, 
and Qp are represented, as well as the different proteins expressed according to the stage of infection.
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gene and the unique Y1Y2 exons of EBNA-LP. This was firstly described in P3HR1 
and Daudi BL cell lines [56]. Subsequently, these cells were shown to be more 
resistant to apoptosis than cells infected by wild-type virus, what would be related 
to the truncated shape of EBNA-LP.
Given the difficulty of sequencing repetitive regions, only few authors have 
sequenced the IR1 region, including the EBNA-LP coding region. Previous studies 
identified two EBNA-LP distinct isoforms, type 1 and type 2 variants, based on the 
presence of G8/T12 or V8/A12 in exon W1 [57]. The Q54R substitution was also 
described in exon W2 from an African type 2 spontaneous lymphoblastoid cell line 
LCL [58]. Despite this, a high degree of conservation was reported for the Wp pro-
moter and the W1-W2 intron, while the most diversity was observed for the BWRF1 
ORF, which only shows 80% homology between various strains, and for Y exons 
[59]. The sequence variations in the Y exons, and especially the Y2 exon, made it pos-
sible to define four main subgroups, called A, B, C, and Z. The Akata strain belongs 
to subgroup A and B95-8 to subgroup B. Subgroup Z is found in type 2 EBVs, and 
the C subtype is characterized by V95E and V102I. Finally, it has been reported that 
tumor-derived strains are more prone to interstrain genetic exchange in IR1 [59].
4.4 LMP1
LMP1 is considered to be the main oncogenic protein in EBV. LMP1 is a multi-
functional self-aggregating protein essential for the transformation of human B 
cells and rodent fibroblasts [60]. It is a 386 aa protein comprising a 24 aa cytosolic 
N-terminal (NT) segment, a 162 aa portion consisting of six transmembrane (TM) 
domains, and a 200 aa cytosolic C-terminal (CT) domain (Figure 5) [61]. The NT 
domain plays an important role in the orientation and anchoring of LMP1 to the 
membrane and its constitutive aggregation, thus contributing to the transform-
ing function of LMP1 [62]. The TM region is involved in the localization of LMP1 
at the level of lipid rafts in the membrane, thus inducing its clustering to activate 
signaling from the CT tail. It is remarkable that the F38LWY41 pattern in the first 
transmembrane fragment (TM1) and a second pattern consisting of aa W98 in 
Figure 4. 
Sequence of EBNA-LP protein, with the position of the corresponding exons opposite. Conserved regions are 
represented as well as the key positions. Phosphorylated serins are mentioned by an asterisk.
Figure 5. 
Schematic representation of basic structure of LMP1 protein with the different motifs and their position. 
TM1–6: transmembrane domains 1–6. The FWLY pattern in TM1 and W98 in TM3 are essential for the 
association of TM1–2 with TM3–6 and oligomerization signaling. CTAR1–3: carboxyl-terminal activating 
regions 1–3. PQQAT pattern is necessary for the attachment of TRAF adapters. YYD pattern is essential for 
binding the TNF receptor-associated death domain (TRADD) adapter.
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TM3 are essential for the association of TM domains (1–2) with TM domains 
(3–6) as well as for the oligomerization and signaling of LMP1 [63]. The CT part is 
involved in the activation of LMP1-induced cell signaling pathways, including two 
important regions, CTAR1/TES1 and CTAR2/TES2 (Carboxyl-Terminal Activating 
Region/Transformation Effector Site) critical for EBV-mediated B-cell growth 
transformation [64]. Together, these regions mimic CD40, a member of the tumor 
necrosis factor (TNF) receptor family and key B-cell costimulatory receptor, thus 
enabling the recruitment of cell adapters associated with the TNF receptor family, 
TNF receptor-associated factors (TRAFs). The CTAR1 region includes the P204-
X-Q206-X-T208 consensus pattern necessary for the attachment of TRAF adapters, 
specifically TRAF1, TRAF2, TRAF3, and TRAF5 [65]. Within the CTAR2 region, 
the Y384-Y385-D386 pattern is essential for binding the TNF receptor-associated death 
domain (TRADD) adapter. There is a third region, CTAR3 (aa 232–350), that is 
not essential for in vitro B cell immortalization and is less well known [66]. In this 
region located between CTAR1 and CTAR2 (aa 253–302), a variable number of 
repeat 11 aa elements (4 repeats for B95-8) exist.
LMP1 acts principally as a viral pseudoreceptor, which regulates host cell signal 
transduction by constitutive activation of cell pathways as mitogen-activated 
protein kinase (MAPK) pathways and principally the extracellular regulated kinases 
1 and 2 (ERK1/2), c-Jun amino-terminal kinases 1–3 (JNK1–3), and p38 isoform 
pathways. LMP1 also induces the phosphatidylinositol 3-kinase (PI3K) pathway, 
which contributes to survival signals [67] and transcription of activator protein 1 
(AP1) [68], PI3K, and AP1 pathways, therefore playing a major role in proliferation 
and cell cycle control. LMP1 is also responsible for the activation of JAK/STAT and 
interferon regulatory factor 7 (IRF7) pathways and for aberrant constitutive NF-kB 
activation. Indeed, the CTAR1 PXQXT pattern is able to engage TRAFs, leading 
finally to the activation of noncanonical NF-kB pathway that controls processing of 
the NF-kB2/p100 precursor [69]. The CTAR2 YYD pattern is in turn implicated in 
the activation of the canonical NF-kB pathway [70] after binding of tumor necrosis 
factor receptor superfamily member 1A (TNFRSF1A)-associated via TRADD and 
receptor-inter-acting protein 1 (RIP1). A wider region of LMP1 seems to be respon-
sible for binding RIP1 (aa 351–386), compared to TRADD (aa 375–386) [71]. NF-kB 
is considered to be the principal factor by which LMP1 regulates gene expression 
and modifies cell behavior [72]. Activation of NF-kB is associated with upregula-
tion of anti-apoptotic genes [32, 73] and downregulation of pro-apoptotic factors, 
as well as induction of tumorigenesis-associated B-cell activation markers [74, 75]. 
CTAR3, less well defined, seems to activate SUMOylation pathways and participate 
in the maintenance of EBV latency and control of cell migration, a hallmark of 
oncogenesis [76, 77].
Besides its ability to transform B cells, during the latency state, LMP1 seems also 
to be able to facilitate the release of virions from B cells during lytic replication [32].
Variations in the LMP1 sequence have been widely studied, particularly in the 
context of its impact on clinical occurrence or evolution. A 30 bp deletion (del30), 
resulting in a 10 aa loss in the C-terminal (aa 343–352), was first described in the 
Cao cell isolate from a Chinese NPC [78]. In addition, this isolate harbored numer-
ous substitutions. A high prevalence of the same deletion, as reviewed by Chang 
et al. [8], was found in Asian NPC biopsy tissues [79, 80], in lymphomas and 
EBV-related gastric cancers from Eastern Asia [81] and in Asian nasal NK/T-cell 
lymphomas [82, 83]. Del30 was shown to be often associated with the G335D muta-
tion in NPC, and such strains were reported to have a greater transforming activity 
in vitro than the reference LMP1 [84, 85]. If the 30 bp deletion is partly localized to 
CTAR2, it does not alter NF-kB activation [86] and finally does not modify signaling 
11
EBV Genome Mutations and Malignant Proliferations
DOI: http://dx.doi.org/10.5772/intechopen.93194
Region concerned Mutation Consequence of the mutation References
NT domain (24AA) 
Mutation rate: 0.33
E2D [85, 97]
H3R/L [85, 93, 97]
R7S [85]
G8A [85]
G11S [85]
P12A [85]
R13P [85, 98]
R17L [98, 85]
TM1 (20AA) 
Mutation rate: 0.15
L25I/M [13, 85, 93, 97, 98]
L33I [85]
V43I [85, 93, 97]
D46N [85, 93, 97, 98] 
TM2 (21AA) 
Mutation rate: 0.19
S57A [85, 93, 97]
M61I [85, 98]
I63 V/L [85, 93, 97, 98]
F70V [93]
TM3 (21AA)
Mutation rate: 0.24
A82G
Homo-oligomerization and/or 
interaction with other molecules in  
lipid rafts
[85, 98]
C84G/V [85, 98]
I85L [85, 93, 97, 98]
T91I [85]
I95S [85]
TM4 (21AA) 
Mutation rate: 0.43
F106V/Y
Homo-oligomerization and/or 
interaction with other molecules in  
lipid rafts
[85, 97, 98]
V110L [85]
F112Y [93]
G115A [85]
W116C [85]
V119A [85]
L120F [85]
I122L [85, 93, 98]
I124G/V I124V + I152L: increased NF-kB 
activation in vitro
[93, 96, 97]
L126F
M129I: increased LMPI half-life in 
epithelial cells
[85, 93, 97, 98]
M129I [85, 93, 97, 98]
I137L [85]
TM5 (22AA) 
Mutation rate: 0.18
F144I/D FI44I/D + D150A/L + L151I: increased 
NF-kB activation in vitro
[85, 96, 98]
D150A D150A/L + F144I/D + LI511: increased 
NF-kB activation in vitro
[85, 96, 98]
L151I L151I + F144I/D + D150A/L: increased 
NF-kB activation in vitro
[85, 93, 96–98]
II52L I152L + I124V: increased NF-kB activation 
in vitro
[93, 96, 97]
TM6 (21AA) 
Mutation rate: 0.05
L178M [85, 98]
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Region concerned Mutation Consequence of the mutation References
CTAR1 (45AA) 
Mutation rate: 0.15
Q189P [85, 98]
S192T [85, 98]
G212S/T G212S: Erk activation, thus c-Fos 
induction and binding to API site
[85, 93, 97, 98]
SNQ pattern (212–214) + del30 in NK/T 
biopsies
H213N SNQ pattern (212–214) + del30 in NK/T 
biopsies
[85, 93, 97]
E214Q SNQ pattern (212–214) + del30 in NK/T 
biopsies
[85, 93, 97]
H225L [85]
S229T [93, 98]
P245H [85]
G248D [85]
D250N [85]
N251Y [23]
G252D [85]
CTAR3 (56AA) 
Mutation rate: 0.20
del275–279 [85, 93]
D293G [93]
D298A [85, 98]
H308Q [23]
S309N S309N + del30 + dell5 in NK/T biopsies [85, 93, 97, 98]
G318K [98]
Q322E/N/K [85, 93, 97, 98]
E325D [98]
V327L [98]
E328A [85]
K330A
G331Q [85]
D333N [93]
Q334R [85, 93, 97, 98]
G335D/S [85, 93, 98]
del343–352 [23, 85, 93, 98]
CTAR2 (35AA) 
Mutation rate: 0.23
L338S/P [85, 93, 97, 98]
G344A/D [85, 98]
H348D [93]
H352R [93, 98]
G353D [85]
G355A/I [85]
D356M [85]
S366A/Q/T S366T: Erk activation, thus c-Fos 
induction and binding to AP1 site
[85, 93, 97, 98]
Table 3. 
LMP1 mutations described in the literature.
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properties [87]. However, it is clear that strains bearing del30 are selected over the 
wt-LMP1 variants in NK/T-cell lymphomas [82] and NPC tumors [88]. Given that 
del30 strains have been currently detected in normal carriers [89] or in various 
EBV-associated diseases [90], and, because of a low prevalence of del30 strains in 
samples from Africa, North America, and Europe [8, 91], it is generally admitted 
that LMP1 del30 may represent a geographic polymorphism rather than a disease-
associated polymorphism [92]. In a study, we carried out in France in patients with 
NK/T lymphoma, we found a del30 EBV in 4/4 biopsies studied and in 46.1% of 
total blood samples analyzed, while in a control population, the deletion was present 
in 4.8% of cases [93]. Other deletions were also described, such as the rare C termi-
nal 69 bp deletion reported to weakly activate the AP1 transcription factor [94], or 
the 15 bp deletion (aa 275–279) frequently encountered in Western Europe [93].
Otherwise, numerous substitutions have been described in LMP1 (Table 3), 
particularly in the N-terminal extremity. Some authors have made attempts to 
classify viral strains by taking into account these substitutions with the aim of 
highlighting a viral implication in certain pathologies [95]. Thus, Mainou and 
Raab-Traub [87] classified EBV into seven variants, namely Alaskan, China 1, China 
2, Med+, Med-, NC, and B95-8, all having the same in vitro transforming potential 
and signaling properties. Zuercher et al. [96] mentioned two polymorphisms, 
I124V/I152L and F144I/D150A/L151I, which seem to be markers of increased NF-kB 
activation in vitro. Lei et al. [97] distinguished four models according to the substi-
tutions occurring in both the LMP1 gene and its promoter. The patients suffering 
from NPC that they studied all carried a strain belonging to pattern B, while the 
BLs were distributed among the four patterns. Many authors recognize two evolu-
tionarily distinct clusters, Asian-derived EBV strains including GD2, HKNPC1, and 
Akata strains and non-Asian and African/American strains including AG876, B95-8, 
and Mutu strains, suggesting that the LMP1 gene could be used as a geographic 
marker [25, 98].
Finally, it should be noted that LMP1 carries a molecular signature of acceler-
ated evolution rate probably due to positive selection as deduced from a significant 
proportion of nonsignificant variations [26].
So, regarding LMP1, which is the most oncogenic latency protein, two geo-
graphic clusters appear to exist corresponding to an Asian variant and a non-Asiatic 
variant. The described 30 bp deletion is mainly present on Asian strains, and it 
shows an obvious tropism for nasopharynx. Although many substitutions have been 
described, little work is done to analyze changes in LMP1 properties based on these 
substitutions. NPC could be associated with a particular strain, but this remains to 
be confirmed.
5. Variability of tegument proteins
After the latency proteins, the tegument proteins carry the most changes, and 
among them, the most mutated are BNRF1, BPLF1, and BKRF3, which will be 
detailed, as well as BBRF2. This latter protein appears to play an important role in 
viral infectivity [99], but its structure and function are poorly known today. For 
this reason, BBRF2 will not be developed here.
5.1 BNRF1
EBV major tegument protein BNRF1 contains 1318 aa, and its structure is shown 
schematically in Figure 6. BNRF1 is a member of a protein family with homology 
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to the cellular purine biosynthesis enzyme FGARAT. BNRF1 is involved in the 
establishment of latency and cell immortalization by hijacking the antiviral DAXX 
(death domain-associated protein-6) histone chaperone [100]. BNRF1 seems to 
have lost conventional purine biosynthesis activity. It forms a stable quaternary 
complex with DAXX histone-binding domain (HBD), H3.3 and H4 [101], respon-
sible for BNRF1 localization to PML nuclear bodies involved in antiviral intrinsic 
resistance and transcriptional repression of host cells. In the presence of BNFR1, 
DAXX can no longer collaborate with ATRX to assemble histone variant H3.3 into 
repressive chromatin at GC-rich repetitive DNA. Binding to DAXX, histone H3.3 
and histone H4 occur, respectively, via the BNRF1 DAXX interaction domain (DID) 
(aa 360–600) and BNRF1 residues 40–52 and 99–102. Huang et al. [101] demon-
strated that the quaternary complex formation is abrogated when dual mutations 
V546D/L548D and D568A/D569A occurred on BRNF1 DID and is partially dimin-
ished in vitro in case of dual mutations Y390A/K461A and V546S/L548S on BNRF1 
DID. BNRF1 mutations at K461A, Y390A/K461A, V546S/L548S or Y390A, V546A/
L548A, and D568A/569A moderately or severely reduced BNRF1 colocalization at 
PML nuclear bodies, respectively. A PurM-like domain (610–976) and a GATase 
domain (1037–1318) were defined. It has also recently been shown that BNRF1 can 
cause an abnormal increase in the number of cellular centrioles [102]. This phenom-
enon can lead to aneuploidy or structural chromosome abnormalities and, possibly, 
to carcinogenesis. The gene regions concerned have not been described.
BNRF1 is reported to be one of the most frequently mutated tegument proteins. 
It is interesting to note that a nonsense mutation was described in C666–1, an EBV-
positive NPC cell line, with no major structural alterations in the BNRF1-deleted 
virus [91].
So, the mutations described for BNRF1 do not appear to correspond to a particu-
lar geographical distribution. On the other hand, some mutations seem to be able to 
modify DNA chromatinization, thus affecting the transcription, and therefore have 
important consequences on cell functioning.
5.2 BPLF1
BPLF1, the largest EBV protein (3149 aa), is a late lytic tegument protein. BPLF1 
possesses a deubiquitinating (DUB) activity. BPLF1 is able to downregulate viral 
ribonucleotide reductase (RR) activity, by deubiquitination of the large subunit 
RR1 [103], and to specifically deubiquitinate proliferating cell nuclear antigen 
(PCNA), a DNA polymerase processivity factor, thus disrupting the repair of dam-
aged DNA [104]. By triggering activation of repair pathways and co-opting DNA 
repair and replication factors, the virus could create genomic instability. The DUB 
activity is carried by the first 246 aa of the N-terminal region, and the C61 residue 
Figure 6. 
Schematic representation of basic structure of BNRF1 protein with the different motifs and their position. H3.3 
and H4 regions, respectively, involved in binding to H3.3 and H4. DID: DAXX-interaction domain, domain 
implicated in binding to DAXX (death-domain associated protein-6) histone chaperone. PurM-like domain 
and GATase domain were noted, as well as the different mutations discussed.
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of the catalytic triad (Cys-His-Asp) is essential for activity [103]. BPLF1 relocalizes 
Pol 𝜼 to nuclear sites of viral DNA production, thereby bypassing DNA damage 
[105]. This mechanism contributes to efficient production of infectious virus.
BPLF1 is also able to deubiquinate cell factors, such as TRAF6, NEMO, and IkBα, 
leading to TLR signaling inhibition through both MyD88- and TRIF-dependent 
pathways, thus decreasing innate immune responses by reduced NF-kB activation 
and proinflammatory cytokine production [106]. It is noteworthy that the same 
catalytic active site also carries a deneddylating activity shown to target cullin ring 
ligases, potentially affecting viral replication and infectivity [107]. The role of 
BPLF1 to help drive human B-cell immortalization and lymphoma formation has 
also been discussed [108].
Sequencing of various viral strains has shown that BPLF1 is one of the proteins 
with the greatest number of changes [20, 24, 109]. Most of these mutations are not 
analyzed in detail, but Kwok et al. [21], working on the sequences of eight NPC 
biopsy specimens, reported two nonsynonymous mutations in the N-terminal 
region of the protein that exhibit deubiquitinating activity. The same finding 
was reported by Simbiri et al. [109], who also described 3 C-terminal mutations 
(L2935P, P2987L, and R3005Q ). A single-nucleotide deletion coupled with a single-
nucleotide insertion three nucleotides away was reported by Zeng et al. [13] in a 
NPC strain. As a result, two aa substitutions (GA/EG) were predicted to occur. Tu 
et al. [24] undertook phylogenetic analysis based on several reported EBV genome 
sequences and some major genes as BPLF1. They observed that EBV Asian subtypes 
clustered as a separate branch from the non-Asian ones.
So, as with other proteins, it seems that the Asian strains carry a protein dif-
ferent from the other strains. Substitutions occurring in the region carrying the 
deubiquitinase activity could have biological consequences.
5.3 BKRF3
BKRF3 is a small protein (255 aa), which belongs to the early lytic gene family, 
and encodes an uracil-DNA glycosylase (UDG), which removes inappropriate uracil 
residues from DNA. BKRF3 excises uracil bases incorporated in double-stranded 
DNA due to uracil misincorporation or more often cytosine deamination [110, 111]. 
BKRF3 participates in DNA replication and repair and prevents viral DNA muta-
genesis. BKRF3 shares substantial similarity in overall structure with the one 
UDG family. Four of the five catalytic motifs are completely conserved (aa 90–94, 
110–114, 146–149, 191–192), whereas the fifth domain (aa 213–229) carries a seven-
residue insertion in the leucine loop [112]. In addition, the 29 N-terminal aa carry 
a nuclear localization signal (sequence KRKQ ). Only changes in BKRF3 that do not 
severely affect viral replication can be retained, but it may be considered that these 
mutations cause a change in virus-cell interrelations.
6. Conclusion
The aim of this chapter was to take stock of the most frequently observed varia-
tions in the EBV genome and more particularly to see if some of these variations are 
considered to be involved in tumor pathology. The candidate viral genes concerned 
are numerous; those developed here are the most affected, and the mutations 
reported in the literature have been identified. Some mutations have been well 
studied, in particular as regards their impact on the structure or functionality of 
the protein or the cellular consequences of these modifications. However, most 
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mutations have only been described. If a tumorigenic impact of viral mutations 
is not yet certain, many authors agree that geographic variants exist, and it seems 
clear that Asian strains have different characteristics from non-Asian strains. 
Further work is necessary to complete the mass of information and analysis, not at 
the level of one or several genes, but at the level of the entire genome.
© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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